CDKL5 deficiency disorder: clinical features, diagnosis, and management

[1]  Matthew T. Sweney,et al.  Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial , 2022, The Lancet Neurology.

[2]  H. Leonard,et al.  Influences on the trajectory and subsequent outcomes in CDKL5 deficiency disorder , 2021, Epilepsia.

[3]  T. Benke,et al.  Cerebral Visual Impairment in CDKL5 Deficiency Disorder Correlates With Developmental Achievement , 2021, Journal of child neurology.

[4]  E. Pestana-Knight,et al.  Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder , 2021, Journal of Neurodevelopmental Disorders.

[5]  O. Devinsky,et al.  Content Validation of Clinician-Reported Items for a Severity Measure for CDKL5 Deficiency Disorder , 2021, Journal of child neurology.

[6]  H. Leonard,et al.  The perceived effects of cannabis products in the management of seizures in CDKL5 Deficiency Disorder , 2021, Epilepsy & Behavior.

[7]  R. Hansen,et al.  Cerebral visual impairment in CDKL5 deficiency disorder: vision as an outcome measure , 2021, Developmental medicine and child neurology.

[8]  O. Devinsky,et al.  Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder , 2021, Epilepsia.

[9]  D. Mei,et al.  CDKL5 deficiency disorder in males: Five new variants and review of the literature. , 2021, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[10]  R. Toledano,et al.  Sodium channel blockers for the treatment of epilepsy in CDKL5 deficiency disorder: Findings from a multicenter cohort , 2021, Epilepsy & Behavior.

[11]  E. Pestana-Knight,et al.  Brain morphological abnormalities in children with cyclin-dependent kinase-like 5 deficiency disorder. , 2021, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[12]  D. Friedman,et al.  Ataluren for drug‐resistant epilepsy in nonsense variant‐mediated Dravet syndrome and CDKL5 deficiency disorder , 2021, Annals of clinical and translational neurology.

[13]  Masahiro Ito,et al.  Clinical manifestations and epilepsy treatment in Japanese patients with pathogenic CDKL5 variants , 2021, Brain and Development.

[14]  Zhi-Li Huang,et al.  CDKL5 deficiency in forebrain glutamatergic neurons results in recurrent spontaneous seizures , 2021, Epilepsia.

[15]  H. Leonard,et al.  Exploring quality of life in individuals with a severe developmental and epileptic encephalopathy, CDKL5 Deficiency Disorder , 2020, Epilepsy Research.

[16]  E. Marsh,et al.  X-linked cellular mosaicism underlies age-dependent occurrence of seizure-like events in mouse models of CDKL5 deficiency disorder , 2020, Neurobiology of Disease.

[17]  A. Berg,et al.  SCN2A‐Developmental and Epileptic Encephalopathies: Challenges to trial‐readiness for non‐seizure outcomes , 2020, Epilepsia.

[18]  I. Scheffer,et al.  Fenfluramine HCl (Fintepla®) provides long‐term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open‐label extension study , 2020, Epilepsia.

[19]  Katrina Jane Williams,et al.  Functioning, participation, and quality of life in children with intellectual disability: an observational study , 2020, Developmental medicine and child neurology.

[20]  H. Leonard,et al.  Exploring genotype‐phenotype relationships in the CDKL5 deficiency disorder using an international dataset , 2020, Clinical genetics.

[21]  E. Marsh,et al.  Aged heterozygous Cdkl5 mutant mice exhibit spontaneous epileptic spasms , 2020, Experimental Neurology.

[22]  Joni N. Saby,et al.  Comparison of Core Features in Four Developmental Encephalopathies in the Rett Natural History Study , 2020, Annals of neurology.

[23]  O. Devinsky,et al.  Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder , 2020, Neuropharmacology.

[24]  M. Korte,et al.  Fingolimod Modulates Dendritic Architecture in a BDNF-Dependent Manner , 2020, International journal of molecular sciences.

[25]  P. Kind,et al.  Proof-of-concept for a gene replacement approach to CDKL5 deficiency disorder. , 2020, Brain : a journal of neurology.

[26]  M. Kinali,et al.  Gene replacement ameliorates deficits in mouse and human models of cyclin-dependent kinase-like 5 disorder. , 2020, Brain : a journal of neurology.

[27]  H. Mefford.  Phenotype to Genotype and Back Again , 2020, Epilepsy currents.

[28]  J. Eubanks,et al.  Seizures in Mouse Models of Rare Neurodevelopmental Disorders , 2020, Neuroscience.

[29]  D. Bick,et al.  Expanding the phenotype of the CDKL5 deficiency disorder: Are seizures mandatory? , 2020, American journal of medical genetics. Part A.

[30]  R. De Rosa,et al.  The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo , 2020, Neurobiology of Disease.

[31]  R. Śmigiel,et al.  CDKL5 Deficiency Disorder—A Complex Epileptic Encephalopathy , 2020, Brain sciences.

[32]  H. O'Geen,et al.  Artificial escape from XCI by DNA methylation editing of the CDKL5 gene , 2020, Nucleic acids research.

[33]  R. De Rosa,et al.  Pregnenolone and pregnenolone-methyl-ether rescue neuronal defects caused by dysfunctional CLIP170 in a neuronal model of CDKL5 Deficiency Disorder , 2019, Neuropharmacology.

[34]  A. Mctague,et al.  Epilepsy and developmental disorders: Next generation sequencing in the clinic. , 2019, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[35]  J. Wang,et al.  Phenotypic manifestations between male and female children with CDKL5 mutations , 2019, Brain and Development.

[36]  M. Pinotti,et al.  Splicing Mutations Impairing CDKL5 Expression and Activity Can be Efficiently Rescued by U1snRNA-Based Therapy , 2019, International journal of molecular sciences.

[37]  R. De Rosa,et al.  Microtubules: A Key to Understand and Correct Neuronal Defects in CDKL5 Deficiency Disorder? , 2019, International journal of molecular sciences.

[38]  E. Pestana-Knight,et al.  Severity Assessment in CDKL5 Deficiency Disorder. , 2019, Pediatric neurology.

[39]  E. Pestana-Knight,et al.  Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review. , 2019, Pediatric neurology.

[40]  H. Mefford,et al.  Genetic heterogeneity in infantile spasms , 2019, Epilepsy Research.

[41]  E. Pestana-Knight,et al.  CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development , 2019, Epilepsia.

[42]  D. Pilz,et al.  Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort , 2019, Brain : a journal of neurology.

[43]  N. Landsberger,et al.  Aminoglycoside drugs induce efficient read-through of CDKL5 nonsense mutations, slightly restoring its kinase activity , 2019, RNA biology.

[44]  E. Marsh,et al.  Altered NMDAR signaling underlies autistic-like features in mouse models of CDKL5 deficiency disorder , 2019, Nature Communications.

[45]  F. Jensen,et al.  AMPA Receptor Dysregulation and Therapeutic Interventions in a Mouse Model of CDKL5 Deficiency Disorder , 2019, The Journal of Neuroscience.

[46]  P. Striano,et al.  Clinical evolution and epilepsy outcome in three patients with CDKL5-related developmental encephalopathy. , 2019, Epileptic disorders : international epilepsy journal with videotape.

[47]  O. Dulac,et al.  New insights in phenomenology and treatment of epilepsy in CDKL5 encephalopathy , 2019, Epilepsy & Behavior.

[48]  Nihal Olgac Dundar,et al.  A new cause of developmental and epileptic encephalopathy with continuous spike-and-wave during sleep: CDKL5 disorder , 2019, Neurocase.

[49]  H. Leonard,et al.  A framework for understanding quality of life domains in individuals with the CDKL5 deficiency disorder , 2019, American journal of medical genetics. Part A.

[50]  Z. Xiong,et al.  Molecular and Synaptic Bases of CDKL5 Disorder , 2018, Developmental neurobiology.

[51]  Katrina Jane Williams,et al.  Psychometric properties of the Quality of Life Inventory-Disability (QI-Disability) measure , 2018, Quality of Life Research.

[52]  P. Eyers.  A new consensus for evaluating CDKL5/STK9‐dependent signalling mechanisms , 2018, The EMBO journal.

[53]  Annapurna Poduri,et al.  The ClinGen Epilepsy Gene Curation Expert Panel—Bridging the divide between clinical domain knowledge and formal gene curation criteria , 2018, Human mutation.

[54]  C. Hatton,et al.  Prevalence of constipation in people with intellectual disability: A systematic review , 2018 .

[55]  H. Hiscock,et al.  Sleep in children with neurodevelopmental difficulties , 2018, Journal of paediatrics and child health.

[56]  H. Leonard,et al.  Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder , 2018, Epilepsy Research.

[57]  John Rouse,et al.  Phosphoproteomic screening identifies physiological substrates of the CDKL5 kinase , 2018, The EMBO journal.

[58]  A. Muotri,et al.  Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics , 2018, The EMBO journal.

[59]  L. Petrucelli,et al.  Converging pathways in neurodegeneration, from genetics to mechanisms , 2018, Nature Neuroscience.

[60]  Anup D. Patel,et al.  Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes , 2018, Epilepsy & Behavior.

[61]  I. Scheffer,et al.  The phenotype of SCN8A developmental and epileptic encephalopathy , 2018, Neurology.

[62]  K. Holman,et al.  Diagnostic yield of targeted massively parallel sequencing in children with epileptic encephalopathy , 2018, Seizure.

[63]  Amanda S. Lindy,et al.  Diagnostic outcomes for genetic testing of 70 genes in 8565 patients with epilepsy and neurodevelopmental disorders , 2018, Epilepsia.

[64]  E. Ciani,et al.  Treatment with the GSK3‐beta inhibitor Tideglusib improves hippocampal development and memory performance in juvenile, but not adult, Cdkl5 knockout mice , 2018, The European journal of neuroscience.

[65]  H. Leonard,et al.  Comparing Parental Well-Being and Its Determinants Across Three Different Genetic Disorders Causing Intellectual Disability , 2017, Journal of Autism and Developmental Disorders.

[66]  S. Bastianini,et al.  CDKL5 protein substitution therapy rescues neurological phenotypes of a mouse model of CDKL5 disorder , 2018, Human molecular genetics.

[67]  Erika Axeen,et al.  Neonatal epilepsy genetics. , 2018, Seminars in fetal & neonatal medicine.

[68]  Mark Quigg,et al.  Quality of life in adults with epilepsy is associated with anticonvulsant polypharmacy independent of seizure status , 2018, Epilepsy & Behavior.

[69]  Amanda S. Lindy,et al.  High frequency of mosaic pathogenic variants in genes causing epilepsy-related neurodevelopmental disorders , 2017, Genetics in Medicine.

[70]  S. Cobb,et al.  CDKL5 variants , 2017, Neurology: Genetics.

[71]  R. Bowman,et al.  Is there consensus in defining childhood cerebral visual impairment? A systematic review of terminology and definitions , 2017, British Journal of Ophthalmology.

[72]  L. Bennet,et al.  Ganaxolone: A New Treatment for Neonatal Seizures , 2017, Front. Cell. Neurosci..

[73]  S. Bastianini,et al.  CDKL5 deficiency entails sleep apneas in mice , 2017, Journal of sleep research.

[74]  A. Mallick,et al.  Caregiver's perception of epilepsy treatment, quality of life and comorbidities in an international cohort of CDKL5 patients. , 2017, Hippokratia.

[75]  A. Bergin,et al.  Use of the ketogenic diet to manage refractory epilepsy in CDKL5 disorder: Experience of >100 patients , 2017, Epilepsia.

[76]  D. Segal,et al.  Genetics and genotype–phenotype correlations in early onset epileptic encephalopathy with burst suppression , 2017, Annals of neurology.

[77]  H. Leonard,et al.  Impacts of caring for a child with the CDKL5 disorder on parental wellbeing and family quality of life , 2017, Orphanet Journal of Rare Diseases.

[78]  J. Christodoulou,et al.  Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder , 2016, Neurology.

[79]  J. Christodoulou,et al.  Functional abilities in children and adults with the CDKL5 disorder , 2016, American journal of medical genetics. Part A.

[80]  H. Leonard,et al.  Prevalence and onset of comorbidities in the CDKL5 disorder differ from Rett syndrome , 2016, Orphanet Journal of Rare Diseases.

[81]  Micah O. Mazurek,et al.  Sleep and Behavioral Problems in Children with Autism Spectrum Disorder , 2016, Journal of autism and developmental disorders.

[82]  P. Striano,et al.  Retrospective evaluation of low long-term efficacy of antiepileptic drugs and ketogenic diet in 39 patients with CDKL5-related epilepsy. , 2016, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[83]  J. Christodoulou,et al.  There is variability in the attainment of developmental milestones in the CDKL5 disorder , 2015, Journal of Neurodevelopmental Disorders.

[84]  Meredith Wilson,et al.  The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy , 2012, European Journal of Human Genetics.

[85]  I. Scheffer,et al.  A distinctive seizure type in patients with CDKL5 mutations: Hypermotor-tonic-spasms sequence , 2011, Neurology.

[86]  S. Savasta,et al.  CDKL5 gene‐related epileptic encephalopathy: electroclinical findings in the first year of life , 2011, Developmental medicine and child neurology.

[87]  W. Kaufmann,et al.  Rett syndrome: Revised diagnostic criteria and nomenclature , 2010, Annals of neurology.

[88]  N. Boddaert,et al.  Key clinical features to identify girls with CDKL5 mutations. , 2008, Brain : a journal of neurology.

[89]  N. Boddaert,et al.  The three stages of epilepsy in patients with CDKL5 mutations , 2008, Epilepsia.

[90]  G. Forlani,et al.  Functional Consequences of Mutations in CDKL5, an X-linked Gene Involved in Infantile Spasms and Mental Retardation* , 2006, Journal of Biological Chemistry.

[91]  J. Christodoulou,et al.  Predictors of seizure onset in Rett syndrome. , 2006, The Journal of pediatrics.

[92]  J. Gécz,et al.  Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. , 2004, American journal of human genetics.

[93]  J. Gécz,et al.  Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation. , 2004, American journal of human genetics.

[94]  F. Hanefeld.  The clinical pattern of the rett syndrome , 1985, Brain and Development.